ATE314116T1 - Verwendung von roxithromycin zur herstellung eines medikaments zur verbesserung der biologischen und antiviralen aktivität von protease-inhibitoren - Google Patents

Verwendung von roxithromycin zur herstellung eines medikaments zur verbesserung der biologischen und antiviralen aktivität von protease-inhibitoren

Info

Publication number: ATE314116T1
Authority: AT; Austria
Prior art keywords: protease inhibitors; roxithromycin; medication; biological; producing
Prior art date: 1995-08-30

Application number

AT96929058T

Other languages

English (en)

Inventor

Raymond F Schinazi

Jean-Pierre Sommadossi

Original Assignee

Uab Research Foundation

Raymond F Schinazi

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-08-30

Filing date

1996-08-30

Publication date

2006-01-15

1996-08-30 Application filed by Uab Research Foundation, Raymond F Schinazi filed Critical Uab Research Foundation

2006-01-15 Application granted granted Critical

2006-01-15 Publication of ATE314116T1 publication Critical patent/ATE314116T1/de

Links

239000000137 peptide hydrolase inhibitor Substances 0.000 title abstract 4
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 title abstract 2
239000003814 drug Substances 0.000 title abstract 2
RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 title 1
230000000840 anti-viral effect Effects 0.000 title 1
230000004071 biological effect Effects 0.000 title 1
229940079593 drug Drugs 0.000 title 1
229960005224 roxithromycin Drugs 0.000 title 1
229940124158 Protease/peptidase inhibitor Drugs 0.000 abstract 2
229940122440 HIV protease inhibitor Drugs 0.000 abstract 1
239000003242 anti bacterial agent Substances 0.000 abstract 1
229940088710 antibiotic agent Drugs 0.000 abstract 1
230000004700 cellular uptake Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
239000004030 hiv protease inhibitor Substances 0.000 abstract 1
239000003120 macrolide antibiotic agent Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
229940124597 therapeutic agent Drugs 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/14—Acyclic radicals, not substituted by cyclic structures attached to a sulfur, selenium or tellurium atom of a saccharide radical
- C07H15/16—Lincomycin; Derivatives thereof
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Tropical Medicine & Parasitology (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
AIDS & HIV (AREA)
Crystallography & Structural Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT96929058T 1995-08-30 1996-08-30 Verwendung von roxithromycin zur herstellung eines medikaments zur verbesserung der biologischen und antiviralen aktivität von protease-inhibitoren ATE314116T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/521,474 US5750493A (en)	1995-08-30	1995-08-30	Method to improve the biological and antiviral activity of protease inhibitors
PCT/US1996/013721 WO1997008180A1 (en)	1995-08-30	1996-08-30	Method to improve the biological and antiviral activity of protease inhibitors

Publications (1)

Publication Number	Publication Date
ATE314116T1 true ATE314116T1 (de)	2006-01-15

Family

ID=24076871

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT96929058T ATE314116T1 (de)	1995-08-30	1996-08-30	Verwendung von roxithromycin zur herstellung eines medikaments zur verbesserung der biologischen und antiviralen aktivität von protease-inhibitoren

Country Status (11)

Country	Link
US (1)	US5750493A (de)
EP (1)	EP0876387B1 (de)
JP (1)	JP4335311B2 (de)
KR (1)	KR100454663B1 (de)
AT (1)	ATE314116T1 (de)
AU (1)	AU716821B2 (de)
DE (1)	DE69635671T2 (de)
DK (1)	DK0876387T3 (de)
ES (1)	ES2257752T3 (de)
PT (1)	PT876387E (de)
WO (1)	WO1997008180A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5849911A (en) *	1996-04-22	1998-12-15	Novartis Finance Corporation	Antivirally active heterocyclic azahexane derivatives
WO1998020888A1 (en) *	1996-11-08	1998-05-22	Japan Energy Corporation	Aids remedy
US6180634B1 (en) *	1997-11-13	2001-01-30	Merck & Co., Inc.	Combination therapy for the treatment of AIDS
ES2140329B1 (es) *	1997-12-04	2000-10-16	Univ Granada	Utilizacion de acido maslinico como inhibidor de proteasas para el tratamiento de la enfermedad causada por los virus de la inmunodeficiencia adquirida.
US6436989B1 (en)	1997-12-24	2002-08-20	Vertex Pharmaceuticals, Incorporated	Prodrugs of aspartyl protease inhibitors
US6734192B1 (en)	1999-08-23	2004-05-11	Mp-1 Inc.	Treatment of viral infections
ITMI992711A1 (it) *	1999-12-27	2001-06-27	Novartis Ag	Composti organici
KR20030011797A (ko) *	2000-03-28	2003-02-11	바이오케미 게젤샤프트 엠베하	맛이 차폐된 과립형 입자
US6566401B2 (en) *	2001-03-30	2003-05-20	The Board Of Trustees Of The Leland Stanford Junior University	N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
US7087373B2 (en)	2001-06-05	2006-08-08	Tibotec Pharmaceuticals Ltd.	Methods for determining plasma free drug concentration by direct measurement of binding affinity of protease inhibitors to plasma proteins
US20040186063A1 (en) *	2002-02-15	2004-09-23	Hans-Jurgen Gutke	Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
WO2003070254A1 (en) *	2002-02-15	2003-08-28	Sympore Gmbh	Antibiotic conjugates
WO2003070174A2 (en)	2002-02-15	2003-08-28	Sympore Gmbh	Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
EP1483579A4 (de) *	2002-02-15	2006-07-12	Merckle Gmbh	Konjugate biologisch aktiver verbindungen, verfahren zu ihrer herstellung und verwendung, formulierung und pharmazeutische anwendungen davon
JP2005517454A (ja) *	2002-02-22	2005-06-16	テイボテク・ビーブイビーエイ	抗レトロウイルス活性に対するヒト血漿もしくは血清タンパク質の結合の影響の決定方法
US20030180279A1 (en) *	2002-03-19	2003-09-25	Tibor Sipos	Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
US20040197321A1 (en) *	2002-03-19	2004-10-07	Tibor Sipos	Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
AU2003231765B9 (en) *	2002-04-26	2010-01-28	Gilead Sciences, Inc.	Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds and the compounds as such
US20050239054A1 (en) *	2002-04-26	2005-10-27	Arimilli Murty N	Method and compositions for identifying anti-HIV therapeutic compounds
EP1556398B1 (de) *	2002-10-31	2009-09-09	Metabasis Therapeutics, Inc.	Cytarabin-monophosphate prodrugs
WO2005027855A2 (en) *	2003-02-21	2005-03-31	Jarrow Formulas, Inc.	Methods for treatment of hiv or malaria using combinations of chloroquine and protease inhibitors
WO2004096287A2 (en) *	2003-04-25	2004-11-11	Gilead Sciences, Inc.	Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
US7407965B2 (en) *	2003-04-25	2008-08-05	Gilead Sciences, Inc.	Phosphonate analogs for treating metabolic diseases
WO2005002626A2 (en) *	2003-04-25	2005-01-13	Gilead Sciences, Inc.	Therapeutic phosphonate compounds
CN101410120A (zh) *	2003-04-25	2009-04-15	吉里德科学公司	抗炎的膦酸酯化合物
US7470724B2 (en) *	2003-04-25	2008-12-30	Gilead Sciences, Inc.	Phosphonate compounds having immuno-modulatory activity
US7432261B2 (en) *	2003-04-25	2008-10-07	Gilead Sciences, Inc.	Anti-inflammatory phosphonate compounds
US7300924B2 (en) *	2003-04-25	2007-11-27	Gilead Sciences, Inc.	Anti-infective phosphonate analogs
US20050261237A1 (en) *	2003-04-25	2005-11-24	Boojamra Constantine G	Nucleoside phosphonate analogs
JP2006524710A (ja) *	2003-04-25	2006-11-02	ギリアードサイエンシーズ，インコーポレイテッド	キナーゼインヒビターホスホネート抱合体
US20090247488A1 (en) *	2003-04-25	2009-10-01	Carina Cannizzaro	Anti-inflammatory phosphonate compounds
PL1628685T3 (pl) *	2003-04-25	2011-05-31	Gilead Sciences Inc	Przeciwwirusowe analogi fosfonianowe
US7452901B2 (en) *	2003-04-25	2008-11-18	Gilead Sciences, Inc.	Anti-cancer phosphonate analogs
AU2004286239A1 (en) *	2003-10-24	2005-05-12	Gilead Sciences, Inc.	Methods and compositions for identifying therapeutic compounds
US7427624B2 (en) *	2003-10-24	2008-09-23	Gilead Sciences, Inc.	Purine nucleoside phosphorylase inhibitory phosphonate compounds
WO2005044308A1 (en) *	2003-10-24	2005-05-19	Gilead Sciences, Inc.	Phosphonate analogs of antimetabolites
DE602004019815D1 (de) *	2003-12-22	2009-04-16	Gilead Sciences Inc	4'-substituierte carbovir- und abacavir-derivate sowie verwandte verbindungen mit hiv- und hcv-antiviraler wirkung
US20050153990A1 (en) *	2003-12-22	2005-07-14	Watkins William J.	Phosphonate substituted kinase inhibitors
BRPI0418031A (pt) *	2003-12-22	2007-04-17	Gilead Sciences Inc	inibidores de quinase fosfonato-substituìdos
EP1778251B1 (de)	2004-07-27	2011-04-13	Gilead Sciences, Inc.	Nukleosid phosphonat konjugate als anti hiv mittel
CA2615581A1 (en) *	2005-07-26	2007-02-01	Merckle Gmbh	Macrolide conjugates of pyrrolizine and indolizine compounds as inhibitors of 5-lipooxygenase and cyclooxygenase
US8080528B2 (en) *	2005-12-22	2011-12-20	The Releef Initiative	Compositions and methods for treatment of cachexia
ES2359770T3 (es) *	2007-06-22	2011-05-26	Bristol-Myers Squibb Company	Composiciones en comprimidos que contienen atazanavir.
JP2010530892A (ja) *	2007-06-22	2010-09-16	ブリストル−マイヤーズスクイブカンパニー	アタザナビルを含む錠剤組成物
SI2170292T1 (sl) *	2007-06-22	2014-05-30	Bristol-Myers Squibb Holdings Ireland	Tabletirani sestavki, ki vsebujejo atazanavir
JP2010530889A (ja) *	2007-06-22	2010-09-16	ブリストル−マイヤーズスクイブカンパニー	アタザナビルを含む錠剤組成物
AU2009268681B2 (en) *	2008-07-08	2014-10-02	Gilead Sciences, Inc.	Salts of HIV inhibitor compounds
US20100021505A1 (en) *	2008-07-28	2010-01-28	Tibor Sipos	Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
US10449210B2 (en)	2014-02-13	2019-10-22	Ligand Pharmaceuticals Inc.	Prodrug compounds and their uses
CN106687118A (zh)	2014-07-02	2017-05-17	配体药物公司	前药化合物及其用途
FR3049861A1 (fr) *	2016-04-07	2017-10-13	Univ Claude Bernard Lyon	Nouvelles compositions antivirales pour le traitement de la grippe
EP3661937B1 (de)	2017-08-01	2021-07-28	Gilead Sciences, Inc.	Kristalline formen von ethyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninat (gs-9131) zur behandlung von viralen infektionen
CN111788196A (zh)	2018-01-09	2020-10-16	配体药物公司	缩醛化合物及其治疗用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IE20010533A1 (en) *	1990-11-20	2003-03-05	Abbott Lab	Intermediates for preparing retroviral protease inhibiting compounds
US5461067A (en) *	1993-02-25	1995-10-24	Abbott Laboratories	Retroviral protease inhibiting compounds
US6037157A (en) *	1995-06-29	2000-03-14	Abbott Laboratories	Method for improving pharmacokinetics

1995
- 1995-08-30 US US08/521,474 patent/US5750493A/en not_active Expired - Lifetime
1996
- 1996-08-30 PT PT96929058T patent/PT876387E/pt unknown
- 1996-08-30 KR KR10-1998-0701498A patent/KR100454663B1/ko not_active Expired - Fee Related
- 1996-08-30 EP EP96929058A patent/EP0876387B1/de not_active Expired - Lifetime
- 1996-08-30 AT AT96929058T patent/ATE314116T1/de not_active IP Right Cessation
- 1996-08-30 ES ES96929058T patent/ES2257752T3/es not_active Expired - Lifetime
- 1996-08-30 DE DE69635671T patent/DE69635671T2/de not_active Expired - Lifetime
- 1996-08-30 JP JP51050297A patent/JP4335311B2/ja not_active Expired - Fee Related
- 1996-08-30 WO PCT/US1996/013721 patent/WO1997008180A1/en not_active Ceased
- 1996-08-30 AU AU68601/96A patent/AU716821B2/en not_active Ceased
- 1996-08-30 DK DK96929058T patent/DK0876387T3/da active

Also Published As

Publication number	Publication date
US5750493A (en)	1998-05-12
AU6860196A (en)	1997-03-19
EP0876387A1 (de)	1998-11-11
WO1997008180A1 (en)	1997-03-06
KR19990044262A (ko)	1999-06-25
JP4335311B2 (ja)	2009-09-30
DE69635671D1 (de)	2006-02-02
DK0876387T3 (da)	2006-05-29
ES2257752T3 (es)	2006-08-01
DE69635671T2 (de)	2006-09-07
EP0876387B1 (de)	2005-12-28
AU716821B2 (en)	2000-03-09
KR100454663B1 (ko)	2004-12-29
EP0876387A4 (de)	1999-12-01
PT876387E (pt)	2006-05-31
JP2001500471A (ja)	2001-01-16

Legal Events

Date

Code

Title

Description

2006-12-15

UEP

Publication of translation of european patent specification

Ref document number: 0876387

Country of ref document: EP

2011-05-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE69635671D1 (de)	2006-02-02	Verwendung von roxithromycin zur herstellung eines medikaments zur verbesserung der biologischen und antiviralen aktivität von protease-inhibitoren
WO2003034803A8 (en)	2003-11-27	Methods for determining toxicity reversing agents
ATE276764T1 (de)	2004-10-15	Camptothecin arzneimittelkombinationen mit verringerten nebenwirkungen
JO2373B1 (en)	2006-12-12	W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
DE69910045D1 (de)	2003-09-04	Neue heteroaromatische fructose 1,6-bisphosphatase inhibitoren
TR199903331T2 (xx)	2000-06-21	Farnesil protein transferas engelleyicileri.
NZ504026A (en)	2002-12-20	Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
PT1019040E (pt)	2005-01-31	Inibicao da actividade de p38-quinase por meio de arilureias
ES2133807T3 (es)	1999-09-16	Compuestos de peptidilo y su uso terapeutico como inhibidores de metaloproteasas.
ATE179429T1 (de)	1999-05-15	Cytokine dämpfende substanzen
BRPI0509172A (pt)	2007-08-28	pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento
MX9606386A (es)	1997-03-29	Agentes que afectan la hemostasis trombotica.
ATE306473T1 (de)	2005-10-15	Neue piperazinyl-substituierte pyridylalkan, alken and alkin carboxamide
AU2002248384A1 (en)	2002-08-06	Serpin drugs for treatment of hiv infection and method of use thereof
AP2000001934A0 (en)	2000-12-31	Antipicornaviral compounds, their preparation and use.
BRPI0410467A (pt)	2006-05-30	composições e métodos para tratamento de sìndrome respiratória aguda severa (sars)
DE69535264D1 (de)	2006-11-23	Verfahren zur behandlung von diabetes mittels kgf
ATE300288T1 (de)	2005-08-15	Zusammensetzung enthaltend insulin- sensibilisierenden wirkstoffe und inhibitoren der fruktose-1,6-bisphosphatase (fbpase) zur behandlung von diabetes
WO2002078639A3 (en)	2003-04-10	A method of treating proliferative diseases using eg5 inhibitors
PT1272199E (pt)	2005-05-31	Terapias de combinacao com actividade de lesao vascular
ES2088128T3 (es)	1996-08-01	Aminosulfonilureas inhibidoras de acat.
BR0304963A (pt)	2004-09-28	Compostos, composição farmacêutica, e, métodos para modular a atividade de adenosina em um mamìfero, e para tratar um mamìfero sofrendo de ou suscetìvel às doenças
MX9304070A (es)	1994-02-28	Piperidilamidas, piperidilsulfonamidas y piperidilsulfoxamidas novedosas como inhibidores de la biosintesis del colesterol.
AU2001232736A1 (en)	2001-08-14	Protein c derivatives
DE69818809D1 (de)	2003-11-13	Verfahren zur behandlung von narbengewebe